Publications by authors named "Juan H Paez-Garza"
Purpose: To analyze higher-order aberrations (HOAs) and their visual impact in a pediatric blepharokeratoconjunctivitis (PBKC) cohort compared with healthy controls.
Methods: Prospective case-control study of pediatric patients (≤ 16 years old). Subjects underwent wavefront aberrometry analysis to compare HOAs and their impact on visual quality.
Introduction: Surgical treatment of intermittent exotropia is indicated when periods of monocular deviation become longer or control over deviation deteriorates. However, there is no consensus on the ideal age to perform surgery in patients with intermittent exotropia.
Purpose: To evaluate ocular alignment and sensory results at 12 months of follow-up, in patients who received surgical treatment for intermittent exotropia at ≤4 years or >4 years.
Article Synopsis
- - A 6-hour-old newborn boy was diagnosed with congenital eyelid imbrication syndrome (CEIS), characterized by the upper eyelids overriding the lower eyelids and spontaneous eversion.
- - After a physical examination revealed canthal tendon laxity and eye irritation, the newborn was treated conservatively with lubricant ointment, leading to a complete resolution of symptoms by day 4.
- - This case marks the first report of CEIS in a Hispanic infant, adding to the existing literature that primarily documents cases in Asian patients, often resolving without intervention.
Background/aim: To describe demographic and clinical characteristics, treatment, and visual prognosis of Coats disease in Hispanic patients.
Methods: A retrospective chart review was performed on nine patients (ten eyes) diagnosed with Coats disease in our two clinical centrers from 2004 - 2017.
Results: Mean age at diagnosis was 5.
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
J Ocul Pharmacol Ther
April 2018
Purpose: The purpose of this study was to evaluate the clinical efficacy and safety of a novel ophthalmic solution of pazufloxacin on the ocular surface of patients with bacterial conjunctivitis after 7 days of intervention.
Methods: This is a phase 2, double-blind, controlled, multicenter, clinical trial of 300 subjects, randomized to either a 3 dosing regimen of pazufloxacin 0.6% ophthalmic solution (twice a day [BID], n = 90; 3 times a day [TID], n = 76; 4 times a day [QID], n = 68), moxifloxacin 0.